ERBB2 and breast carcinoma: Moreover, in the case of bevacizumab, the indication for human epidermal growth factor receptor 2 (HER2)‐negative breast cancer has been withdrawn from the US market since 2011, as overall survival was not improved in the post‐marketing clinical trial [13, 33, 34, 35].